Elodie LOHOU

Dr. Elodie LOHOU

University of Picardie Jules Verne, Amiens, Hauts-de-France, France
orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 December 2021 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
MDMarine Duplantier
Marine Duplantier
Elodie LOHOUElodie LOHOU
Elodie LOHOU
Pascal SonnetPascal Sonnet
Pascal Sonnet
The emergence and the dissemination of multidrug-resistant bacteria constitute a major public health issue. Among incriminated Gram-negative bacteria, Pseudomonas aeruginosa has been designated by the WHO as a critical priority threat. During the infection process, this pathogen secretes various virulence factors in order to adhere and colonize host tissues. Furthermore, P. aeruginosa has the capacity to establish biofilms that reinforce its virulence and intrinsic drug resistance. The regulation of biofilm and virulence factor production of this micro-organism is controlled by a specific bacterial communication system named Quorum Sensing (QS). The development of anti-virulence agents targeting QS that could attenuate P. aeruginosa pathogenicity without affecting its growth seems to be a promising new therapeutic strategy. This could prevent the selective pressure put on bacteria by the conventional antibiotics that cause their death and promote resistant strain survival. This review describes the QS-controlled pathogenicity of P. aeruginosa and its different specific QS molecular pathways, as well as the recent advances in the development of innovative QS-quenching anti-virulence agents to fight anti-bioresistance.

13 January 2025 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
MHMarie Hanot
Marie Hanot
Elodie LOHOUElodie LOHOU
Elodie LOHOU
Pascal SonnetPascal Sonnet
Pascal Sonnet
Pseudomonas aeruginosa is one of world’s most threatening bacteria. In addition to the emerging prevalence of multi-drug resistant (MDR) strains, the bacterium also possesses a wide variety of virulence traits that worsen the course of the infections. Particularly, its ability to form biofilms that protect colonies from antimicrobial agents is a major cause of chronic and hard-to-treat infections in immune-compromised patients. This protective barrier also ensures cell growth on abiotic surfaces and thus enables bacterial survival on medical devices. Hence, as the WHO alerted to the need to develop new treatments, the use of anti-biofilm agents (ABAs) appeared as a promising approach. Given the selection pressure imposed by conventional antibiotics, a new therapeutic strategy has emerged that aims at reducing bacterial virulence without inhibiting cell growth. So-called anti-virulence agents (AVAs) would then restore the efficacy of conventional antibiotics (ATBs) or potentiate the effectiveness of the immune system. The last decade has seen the development of ABAs as AVAs against P. aeruginosa. This review aims to highlight the design strategy and critical features of these molecules to pave the way for further discoveries of highly potent compounds.

27 October 2019 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
Elodie LOHOUElodie LOHOU
Elodie LOHOU
ASAndré Sasaki
André Sasaki
ABAgnès Boullier
Agnès Boullier
MDMarine Duplantier
Marine Duplantier
Pascal SonnetPascal Sonnet
Pascal Sonnet
There is an urgent need to propose effective treatments for Alzheimer’s disease (AD). Although the origin of the disease is poorly understood, several therapeutic options have been proposed. The new therapeutic approaches targeting biometal-mediated neurodegenerative pathways appear to be interesting ones. As a continuation of our preceding studies, two novel series of advanced glycation endproducts (AGE)/advanced lipid peroxidation endproducts (ALE) inhibitors have been developed as multifunctional scavengers. This extended work allowed us to highlight the new hydroxypyridinone-diamine hybrid IIa-3 bearing a C4 alkyl linker between the two pharmacophores. This derivative exhibited preserved potent capacities to trap reactive carbonyl species (vicinal diamine function) as well as reactive oxygen species and transition metals (hydroxypyridinone moiety) in comparison with previously described lead compound 1. In addition, its good predicted absorption, distribution, metabolism and excretion (ADME) properties were correlated with a better efficacy to inhibit in vitro methylglyoxal-induced apoptosis in neuronal-like PC12 cells. This new promising agent revealed improved druglikeness and ability to prevent biometal-mediated oxidative and carbonyl stress amplification involved in AD pathogenesis.

19 July 2024 in Drugs and Drug Candidates
Verified
Journal Article
Open access
PDF file
MHMarie Hanot
Marie Hanot
MDMarine Duplantier
Marine Duplantier
CDCeline Dalle
Celine Dalle
YRYani Ren
Yani Ren
SNSophie Da Nascimento
Sophie Da Nascimento
Pascal SonnetPascal Sonnet
Pascal Sonnet
Antibiotic resistance is a critical public health issue. Among the multi-drug resistant microorganisms in question, Pseudomonas aeruginosa has been designated by the WHO as a priority threat. Its virulence is orchestrated through quorum sensing (QS). This sophisticated communication network relies on the release and perception of autoinducers acting as population density indicators. Therefore, the interest of a quorum silencing pharmacological approach has unfolded to quench bacterial pathogenicity without impairing growth. In this article, we reported the development of a family of indazole–quinolone hybrids as anti-virulence agents. These new biaromatic compounds were designed as potential specific QS quenchers against P. aeruginosa. Our transdisciplinary research methodology included their synthesis using palladocatalyzed cross-coupling reactions, as well as their in silico physicochemical and in vitro biological evaluation. The hit 7-chloro-2-indazolyl-4-quinolone Ie shows a promising anti-biofilm and anti-pyocyanin efficiency (35% inhibition at 25 µM and 35% inhibition at 100 µM, respectively) without an anti-pseudomonal bacteriostatic effect. It also demonstrated a moderate eukaryotic cytotoxicity. Its anti-QS properties have been investigated using metabolomic and molecular modelling studies.

8 September 2021
Verified
Conference Paper
Open access
MCMorgane Choquet
Morgane Choquet
MDMarine Duplantier
Marine Duplantier
Elodie LOHOUElodie LOHOU
Elodie LOHOU
CMCatherine Mullié
Catherine Mullié
Pascal SonnetPascal Sonnet
Pascal Sonnet
Over the past few decades, the widespread and inappropriate use of broad spectrum antibiotics strongly contributed to the emergence of highly resistant bacterial strains. Among the ESKAPEE pathogens (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa and Enterobacter spp. and Escherichia coli), A.

30 October 2019
Verified
Conference Paper
Open access
MDMarine Duplantier
Marine Duplantier
Elodie LOHOUElodie LOHOU
Elodie LOHOU
Pascal SonnetPascal Sonnet
Pascal Sonnet
Multi-drug resistant ESKAPEE pathogens are responsible for various nosocomial infections. Considering this serious threat to public health, new efficient treatments are urgently needed.1 The bacterial communication systems, called quorum sensing (QS), constitute a pool of new promising pharmacological targets for the development of antimicrobial molecules. The inhibition of QS could disrupt several intra/inter-species protective interactions (bacterial multiplication, biofilm formation) and virulence pathways. The intervention of three main small signaling molecules was described in the pqs intercellular communication system of P. aeruginosa : the Pseudomonas quinolone signal (PQS), its precursor 2-heptyl-4(1H)-quinolone (HHQ) and the 2‑heptyl‑4‑hydroxyquinoline-N-oxide (HQNO) as a secondary metabolite from this pathway.2 Interestingly, HQNO appears to be a potent respiratory chain inhibitor for various competing microorganisms such as S. aureus.3 Furthermore, HHQ analogues and different 2-heteroaryl-4-quinolone series revealed efficient as QS inhibitors (PQS receptor antagonists) or as type II NADH/quinone oxidoreductase inhibitors.4,5,6 Taking these studies into account, the interest of the quinolone scaffold in the design of QS and respiratory chain inhibitors has emerged. In this context, we aim to develop new antibacterial 2‑heteroaryl‑4‑quinolone series. The synthesis of the first series carrying out pallado-catalyzed C-C or C-N coupling reactions from 2-bromo-4-chloroquinoline precursors will be described in the presentation. Bibliographic references: (1) Expert Rev. Anti Infect. Ther., 2013, 11(3), 297-308 ; (2) Org. Biomol. Chem., 2018, 16, 169-181 ; (3) Curr. Biol., 2016, 26, 195-206 ; (4) Org. Biomol. Chem., 2017, 15, 4620-4630 ; (5) J. Med. Chem., 2012, 55, 1844-1857; (6) J. Med. Chem., 2017, 60, 3703-3726.